Axcella touts interim NASH data but needs cash to stay afloat for 2024 topline readout
Axcella Therapeutics, with an empty bank account looming in the first quarter of next year and a recent setback in a mid-stage long Covid study, is out with some interim data on its NASH drug.
The biotech isn’t yet saying how the drug performed on the primary endpoint of improvement in the nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS), but the first batch of results has sent shares $AXLA soaring nearly 15% before Thursday’s opening bell.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.